Abstract: The present invention provides an antimicrobial combination comprising three different antimicrobial agents The first antimicrobial agent is selected from ceftazidime, polymyxin E, polymyxin B, and pharmaceutically acceptable derivatives thereof; the second antimicrobial agent is selected from zidovudine, doxycycline, fosfomycin and pharmaceutically acceptable derivatives thereof; and the third antimicrobial agent is selected from levofloxacin, doxycycline, fosfomycin, meropenem, rifampicin, gentamicin, polymyxin B/E, and pharmaceutically acceptable derivatives thereof; wherein the combination includes at least one of levofloxacin, doxycycline, rifampicin, fosfomycin, or a pharmaceutically acceptable derivative thereof; provided the combination is not (1) polymyxin E/B, zidovudine and rifampicin or (2) ceftazidime, zidovudine and fosfomycin.

Abstract: The invention provides a combination comprising zidovudine or a pharmaceutically acceptable derivative thereof and an antimicrobial compound selected from nitrofurantoin, mecillinam, fosfomycin, cephalexin and faropenem, or a pharmaceutically acceptable derivative or prodrug thereof. These combinations are particularly useful for the treatment of microbial infections.

Abstract: The invention provides a combination comprising zidovudine or a pharmaceutically acceptable derivative thereof and an antimicrobial compound selected from nitrofurantoin, mecillinam, fosfomycin, cephalexin and faropenem, or a pharmaceutically acceptable derivative or prodrug thereof. These combinations are particularly useful for the treatment of microbial infections.

Abstract: The invention provides a combination comprising zidovudine or a pharmaceutically acceptable derivative thereof and a carbapenem or a pharmaceutically acceptable derivative thereof, optionally with a polymyxin selected from polymyxin E and polymyxin or a pharmaceutically acceptable derivative thereof. This combination is particularly useful for the treatment of microbial infections.

Abstract: The invention provides a combination comprising 4-methyl-8-phenoxy-1-(2-phenylethyl)-2,3-dihydro-1H-pyrrolo[3,2-c]quinoline or a pharmaceutically acceptable derivative thereof, mupirocin or a pharmaceutically acceptable derivative thereof and neomycin or a pharmaceutically acceptable derivative thereof. This triple combination is particularly useful for the treatment and/or prevention of microbial infections.

Abstract: The invention provides a combination comprising a compound of formula (I) or a compound of formula (II) or pharmaceutically acceptable derivatives or prodrugs thereof and a polymyxin selected from polymyxin E and polymyxin B or a pharmaceutically acceptable derivative thereof. This combination is particularly useful for the treatment of microbial infections.

Abstract: The invention provides a combination comprising at least one compound selected from dichlorophen, chlorprothixene, perphenazine, thioridazine, trifluoperazine and edetate or a pharmaceutically acceptable derivative thereof and a carbapenem or a pharmaceutically acceptable derivative thereof. This combination is particularly useful for the treatment of microbial infections.

Abstract: There is provided the use of compounds of formula I wherein R1, R2, R3 and X have meanings given in the description, for the preparation of a medicament for killing clinically latent microorganisms. There is also provided the use of compounds of formula I for treating microbial infections, as well as certain compounds of formula I per se.

Abstract: The invention provides a combination comprising at least one compound selected from metergoline, proglumide, sertraline, hydroflumethiazide, perphenazine, fluphenazine and pimethixene, or a pharmaceutically acceptable derivative thereof, and a polymyxin selected from polymyxin B and colistin, or a pharmaceutically acceptable derivative thereof. This combination is particularly useful for the treatment of microbial infections.

Abstract: The present invention relates to the use of one or more compounds selected from the following: caffeic acid, thymol, aspirin, benzydamine hydrochloride, diclofenac sodium, flurbiprofen, ibuprofen, indomethacin, trifluoperazine hydrochloride, chlorprothixene hydrochloride, triflupromazine hydrochloride, suloctidil, thioridazine hydrochloride, dichlorophen, saccharin and piroxicam, in combination with a polymyxin selected from colistin or polymyxin B or a pharmaceutically acceptable derivative thereof, for use in the treatment of a microbial infection, and in particular for killing clinically latent microorganisms associated with microbial infections. The invention also provides a combination comprising suloctidil or a pharmaceutically acceptable derivative or prodrug thereof, and a polymyxin selected from polymyxin E and polymyxin B or a pharmaceutically acceptable derivative thereof. This combination is particularly useful for the treatment and/or prevention of microbial infections.

Abstract: The invention provides a combination comprising zidovudine or a pharmaceutically acceptable derivative thereof and a carbapenem or a pharmaceutically acceptable derivative thereof, optionally with a polymyxin selected from polymyxin E and polymyxin or a pharmaceutically acceptable derivative thereof. This combination is particularly useful for the treatment of microbial infections.

Abstract: The present invention relates to the use of one or more compounds selected from the following: caffeic acid, thymol, aspirin, benzydamine hydrochloride, diclofenac sodium, flurbiprofen, ibuprofen, indomethacin, trifluoperazine hydrochloride, chlorprothixene hydrochloride, triflupromazine hydrochloride, suloctidil, thioridazine hydrochloride, dichlorophen, saccharin and piroxicam, in combination with a polymyxin selected from colistin or polymyxin B or a pharmaceutically acceptable derivative thereof, for use in the treatment of a microbial infection, and in particular for killing clinically latent microorganisms associated with microbial infections. The invention also provides a combination comprising suloctidil or a pharmaceutically acceptable derivative or prodrug thereof, and a polymyxin selected from polymyxin E and polymyxin B or a pharmaceutically acceptable derivative thereof. This combination is particularly useful for the treatment and/or prevention of microbial infections.

Abstract: The present invention relates to the use of one or more compounds selected from the following: carvacrol, thymol, curcumin and piperidine, in combination with an aminoglycoside, for use in the treatment of a microbial infection, and in particular for killing clinically latent microorganisms associated with microbial infections. The present invention also relates to novel combinations comprising one or more compounds selected from the following: carvacrol, thymol, curcumin and piperidine, in combination with an aminoglycoside, for use in the treatment of microbial infections.

Abstract: The invention provides a combination comprising 4-methyl-8-phenoxy-1-(2-phenylethyl)-2,3-dihydro-1H-pyrrolo[3,2-c]quinoline or a pharmaceutically acceptable derivative thereof, mupirocin or a pharmaceutically acceptable derivative thereof and neomycin or a pharmaceutically acceptable derivative thereof. This triple combination is particularly useful for the treatment and/or prevention of microbial infections.

Abstract: The present invention relates to the use of a combination of an anti-retroviral agent such as zidovudine and anti-microbial agents for killing clinically latent microorganisms associated with microbial infections and to novel combinations comprising an anti-retroviral agent such as zidovudine and anti-microbial agents for the treatment of microbial infections.

Abstract: The invention provides an oral composition comprising 4-methyl-8-phenoxy-1-(2-phenylethyl)-2,3-dihydro-1H-pyrrolo[3,2-c]quinoline or a pharmaceutically acceptable salt and/or solvate thereof and chlorhexidine or a pharmaceutically acceptable salt and/or solvate thereof, wherein the composition is in the form of a mouthwash and comprises about 0.001% w/v to about 0.06% w/v of chlorhexidine or a pharmaceutically acceptable salt and/or solvate thereof. Also provided is an oral composition comprising 4-methyl-8-phenoxy-1-(2-phenylethyl)-2,3-dihydro-1H-pyrrolo[3,2-c]quinoline or a pharmaceutically acceptable salt and/or solvate thereof, chlorhexidine or a pharmaceutically acceptable salt and/or solvate thereof, and a zinc compound.

Abstract: The present invention relates to the use of one or more compounds selected from the following: caffeic acid, thymol, aspirin, benzydamine hydrochloride, diclofenac sodium, flurbiprofen, ibuprofen, indomethacin, trifluoperazine hydrochloride, chlorprothixene hydrochloride, triflupromazine hydrochloride, suloctidil, thioridazine hydrochloride, dichlorophen, saccharin and piroxicam, in combination with a polymyxin selected from colistin or polymyxin B or a pharmaceutically acceptable derivative thereof, for use in the treatment of a microbial infection, and in particular for killing clinically latent microorganisms associated with microbial infections. The invention also provides a combination comprising suloctidil or a pharmaceutically acceptable derivative or prodrug thereof, and a polymyxin selected from polymyxin E and polymyxin B or a pharmaceutically acceptable derivative thereof. This combination is particularly useful for the treatment and/or prevention of microbial infections.

Abstract: There is provided the use of compounds of formula I wherein R1, R2, R3 and X have meanings given in the description, for the preparation of a medicament for killing clinically latent microorganisms. There is also provided the use of compounds of formula I for treating microbial infections, as well as certain compounds of formula I per se.

Abstract: The present invention relates to the use of a combination of an anti-retroviral agent such as zidovudine and an anti-microbial agent for killing clinically latent microorganisms associated with microbial infections and to novel combinations comprising an anti-retroviral agent such as zidovudine and an anti-microbial agent for the treatment of microbial infections.

Abstract: There is provided the use of compounds of formula I wherein R1, R2, R3 and X have meanings given in the description, for the preparation of a medicament for killing clinically latent microorganisms. There is also provided the use of compounds of formula I for treating microbial infections, as well as certain compounds of formula I per se.